ArticleCureus2025
Diagnosis of Prostate Cancer via Transanal Endoscopic Ultrasound-Guided Fine-Needle Biopsy in a Patient With Bone Lesions and a Rapid Clinical Response to Enzalutamide Plus Degarelix.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients presenting with bone lesions suggestive of metastatic prostate cancer, rapid acquisition of diagnostic tissue is essential. Although transrectal ultrasound-guided (TRUS) or transperineal biopsy is standard, these approaches may be impractical in certain clinical settings. Markedly elevated serum prostate-specific antigen (PSA) levels can strongly suggest a prostatic origin, but histological confirmation remains necessary to initiate androgen receptor signaling inhibitor (ARSI)-based therapy. A 67-year-old man presented with diffuse arthralgia, impaired ambulation, and widespread osteosclerotic bone lesions on CT. Serum PSA was markedly elevated (5,230 ng/mL). Pelvic MRI could not be performed because of severe claustrophobia, and TRUS/transperineal biopsy was not feasible due to the absence of urology services at our institution. Bone biopsy was considered but judged less feasible than an endoscopic approach. Transanal endoscopic ultrasound (EUS) revealed a hypoechoic lesion in the right prostatic lobe, and EUS-guided fine-needle biopsy (EUS-FNB) using a 19-gauge needle yielded core tissue demonstrating PSA-positive adenocarcinoma. Despite an initial performance status (PS) of 4, driven primarily by pain, enzalutamide plus degarelix was initiated. The patient experienced rapid improvement in mobility and pain, with PSA falling to 11.3 ng/mL at two months and stable bone lesions on imaging. He returned to work in three months. This case illustrates that transanal EUS-FNB can provide a minimally invasive, feasible, and timely diagnostic option for patients in whom conventional prostate biopsy routes are impractical. Early histologic confirmation enabled prompt initiation of ARSI-based therapy, resulting in rapid symptomatic and biochemical improvement. EUS-FNB may be considered in selected cases of suspected prostate cancer when alternative biopsy approaches are not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.